Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
19 hedge funds and large institutions have $55.3M invested in Urovant Sciences Ltd. in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
1.12% more ownership
Funds ownership: 21.93% → 23.05% (+1.1%)
10% less funds holding
Funds holding: 21 → 19 (-2)
17% less capital invested
Capital invested by funds: $66.8M → $55.3M (-$11.5M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.29M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$378K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$351K |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$133K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.16M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.19M |
| 3 |
Millennium Management
New York
|
-$828K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$325K |
| 5 |
Two Sigma Investments
New York
|
-$129K |
UROV Hedge Fund Activity: Q2 2019 in Review
19 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q2 2019, worth a combined $55.3M — down 17% from $66.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of UROV and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Perceptive Advisors, adding an estimated $8.29M. The largest seller was Adage Capital Partners, cutting an estimated $3.16M.
- 19 institutional investors held Urovant Sciences Ltd. (UROV) as of Q2 2019, down from 21 in Q1 2019.
- Funds reported $55.3M of Urovant Sciences Ltd. stock for Q2 2019, down 17% quarter-over-quarter.
- 2 funds opened new Urovant Sciences Ltd. positions in Q2 2019 and 4 closed out, a net change of -2 holders.
- The largest Urovant Sciences Ltd. buyer in Q2 2019 was Perceptive Advisors, an estimated $8.29M added.
- The largest Urovant Sciences Ltd. seller in Q2 2019 was Adage Capital Partners, an estimated $3.16M sold.
Based on aggregated 13F filings for Q2 2019.